12:00 AM
Feb 13, 2012
 |  BC Week In Review  |  Company News  |  Deals

Aldagen, Cytomedix deal

Wound and tissue repair company Cytomedix acquired regenerative cell therapy play Aldagen in a stock deal valued at about $16 million. Aldagen shareholders, who will own 17% of the combined company, are also eligible for milestones of up to 20.3 million Cytomedix shares, which are valued at $28.4 million based on Cytomedix's...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >